Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

Invivyd Inc. has released positive initial results from its ongoing Phase 1 clinical trial of VYD222, a monoclonal antibody candidate designed to prevent symptomatic COVID-19 in immunocompromised people. The drug has been well-tolerated at all dose levels, with no serious adverse events reported so far. Early serum samples from the first, lowest dose cohort showed strong neutralization activity ..